Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of subcutaneous talquetamab combinations versus daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
MOH_2022-09-29_012064Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of talquetamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Aug 2022; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-09-29_012064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-29_012064.